On a down day for the market, these stocks suffered more than most. Here's why.
News & Analysis: Edge Therapeutics
The biopharma's shares plummeted over 90% after an unexpected trial failure.
Looking for a few biotech stocks that have upside potential? Here's why our investors think you should check out Edge Therapeutics, Aratana Therapeutics, and Alkermes.